The Interventional Pharmacoeconomic Toolbox Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Issues in Oncology

The ASCO Post Staff

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Jun

Today In Oncology

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Related Videos

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

AML All-Oral Regimen Safe and Eases Treatment Administration Burden

Study Identifies Serious Infection Risks Linked to Antibody-Drug Conjugates

Overall Survival With EBRT in Hepatocellular Carcinoma

SCLC With Brain-Only Progression Original or Substitute Systemic Therapy With or Without Brain Radiotherapy

Five-Year Survival Analysis: Neoadjuvant Trastuzumab-Pertuzumab Plus Endocrine Therapy or Chemotherapy in HR-Positive/HER2-Positive Breast Cancer